Budesonide gastro-resistant granules - Dr Falk Pharma

Drug Profile

Budesonide gastro-resistant granules - Dr Falk Pharma

Alternative Names: Budenofalk Granules; Budo-San; Intestifalk

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Falk Pharma
  • Developer Dr Falk Pharma; Merck & Co
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Microscopic colitis
  • Phase II Ulcerative colitis

Most Recent Events

  • 16 Jan 2017 Dr Falk Pharma completes a phase III trial in Microscopic colitis in Netherlands, Spain, Lithuania, Czech Republic, Denmark, Belgium, Sweden, Hungary, Germany (EudraCT2008-005994-36)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Jul 2015 Phase-II clinical trials in Ulcerative colitis in Hungary, Latvia (PO) (EudraCT2014-005635-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top